Objective. To investigate determinants of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), including single nucleotide polymorphisms (SNPs) in the DDAH1, DDAH2 and AGXT2 genes and their associations with prevalent and incident cardiovascular disease (CVD) in older adults with type 2 diabetes mellitus.
Asymmetric dimethylarginine (ADMA) is considered an independent risk factor for cardiovascular (CV) events and mortality in patients with a range of CV risk [1] .
Although ADMA plasma levels were reported to be elevated in patients with type 2 diabetes [2] and insulin resistance [3] , there are discrepancies concerning the association of ADMA with glycemic control and its prognostic value regarding CV disease in diabetes patients [4] [5] [6] [7] [8] . Results from prospective studies reporting that high levels of ADMA predicted cardiovascular events in patients with diabetes mellitus [9-10] could not be confirmed in population-based prospective cohorts [7] . A possible explanation for these conflicting results may be that activity of the enzyme responsible for degradation of ADMA, dimethylarginine dimethylaminohydrolase (DDAH), is influenced by diabetes and diabetes therapy [11] [12] . Variation in the DDAH1 and/or DDAH2 genes were associated with differences in ADMA levels in diabetes subjects [13] , with insulin sensitivity in non-diabetes subjects [14] and predicted major cardiovascular events in diabetes subjects [15] .
Recent evidence indicates that symmetric dimethylarginine (SDMA) might also play a role in diabetes mellitus and CVD. In patients with type 2 diabetes mellitus, SDMA was inversely associated with glycemic control and with insulin resistance in nondiabetic Caucasians [5, 16] . Furthermore, prospective studies found that SDMA was an independent predictor for mortality in patients with CVD [17] [18] . While the majority of ADMA is metabolized by DDAH, SDMA is mainly cleared via the kidneys.
However, both dimethylarginines can also be degraded by the enzyme alanineglyoxylate aminotransferase (AGXT2) [19] [20] ].
There appears to be a complex interaction between dimethylarginines, the genes involved in their metabolism, glycemic control, and cardiovascular disease in patients with diabetes mellitus type 2. Therefore, the aims of this study were to: 
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Research Design and Methods
Study population
The Edinburgh Type 2 Diabetes Study (ET2DS) is a prospective, population-based cohort study of 1066 men and women aged 60-75 years with established type 2 diabetes mellitus, recruited between 2006 and 2007 in the Lothian region of Scotland, UK. The design of the ET2DS and details of the physical examination undertaken at baseline and one year after recruitment have been described previously [21] . The ET2DS population has been shown to be representative of patients aged 60-75 years with type 2 diabetes living in Lothian [22] and subjects returning after one year (n=939) are similar to the original study population [23] .
Genotyping for the current analysis was performed in participants attending the one year examination using DNA extracted from whole blood samples taken at baseline (n=935) and plasma L-arginine and dimethylarginines were measured in 783 of these subjects (data missing at random due to insufficient plasma in stored aliquots). All ET2DS participants were followed up after 4 years for CV events (in 2010-2011).
Use of routine data sources (record linkage) and GP/hospital notes as well as direct patient contact ensured that follow-up for CVD events included all ET2DS participants.
Determination of dimethylarginines
Mass spectrometric determination of L-arginine, ADMA and SDMA plasma samples 
Assessment of CVD events
Prevalent CV disease at baseline was recorded according to pre-defined criteria using a combination of subject report of a doctor diagnosis of disease, positive WHO chest pain questionnaire and positive Edinburgh Claudication questionnaire and ECG findings (Minnesota coded) together with hospital discharge codes from record linkage at the Information and Statistics Division (ISD) of NHS Scotland, details of which have been described previously [22] . Four years after recruitment, participants were followed-up for new CV events using a combination of repeat self-completion identified, 2-3 tagSNPs with an r 2 of at least 0.8 were chosen to cover the whole locus, including SNPs reported to be associated with diabetes (rs2474123 and rs2935) [13] . Linkage equilibrium was assessed using the locus zoom software.
Haplotypes were generated using the Thesias software and analyzed for possible effects. For further analyses, only those haplotypes with an estimated effect were considered. 
Results
Dimethylarginines and clinical characteristics
Clinical characteristics of participants attending the year one research clinic (the total study population used in the current analysis, n=939), and of the study population with plasma dimethylarginine available (n=783), together with their associations with dimethylarginines are summarized in table 1
Association of plasma dimethylarginines with cardiovascular disease
Median (IQR) plasma ADMA levels were statistically significantly higher in subjects with dimethylarginines showed an increase in plasma levels of the respective dimethylarginine from the major to the minor allele, with a maximum increase in ADMA of 0.06 µmol/l for the DDAH1 rs1554597 SNP and a maximum increase of SDMA of 0.17 µmol/l for the AGXT2 rs28305 SNP.
Determinants of plasma dimethylarginines
In univariate regression analysis, SDMA was significantly associated with age, sex, creatinine, L-arginine, diastolic BP, waist-hip-ratio, diabetes duration and prevalent CVD and ADMA was significantly associated with age, sex, creatinine, fasting glucose, L-arginine and triglycerides. SNPs were entered into the regression models individually according to p-value and as common haplotypes restricted to SNPs under linkage equilibrium (DDAH1: rs1554597, rs11161614, rs1146381 and the TTG haplotype; AGXT2: rs28305, rs16899974, rs344156 and the GCG haplotype). Table   4 displays the final models for the multivariate analyses. Addition of further SNPs or analysis by haplotypes did not improve the overall models.
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Association of single nucleotide polymorphisms with cardiovascular disease
The distribution of genotypes did not differ significantly between subjects with or without prevalent CVD for the SNPs we investigated (table 3) . Only weak associations between SNPs in the DDAH1 and the AGXT2 gene and CVD were apparent in the logistic regression analysis, and these did not reach statistical significance after correction for multiple testing. In subgroup analyses, carriers of the AGXT2 rs28305 C allele more frequently had a history of intermittent claudication. In the analysis of this SNP according to genotype, the frequency of prevalent intermittent claudication was 4.6% in the GG genotype, 11.9% in the GC genotype and 33.3% in the CC genotype (p<0.001). In the allelic analysis, intermittent claudication was present in 12.5% of the carriers of the C allele as compared to 5.4% in carriers of the G allele (p<0.001). The age, sex and creatinine adjusted odds ratio (95% CI) for carriers of the C allele was 2. 
Associations with cardiovascular disease
The lack of association of ADMA with CVD in our cohort is in contrast to a number of previous studies. Krzyzanowska and coworkers reported that elevated ADMA levels were associated with macrovascular disease in diabetic patients [26] . Furthermore, ADMA was predictive of future CV events and all-cause mortality in two different cohorts of diabetes patients [9,10]. However, data from two larger study collectives recently published showed ADMA levels to be associated with cardiovascular events and all-cause mortality only in non-diabetes patients [7, 15] . In our large cohort of diabetes patients, only weak associations of ADMA with clinical features of diabetes and no association with medication was apparent, making it less likely that glycemic control or medication directly affects ADMA and its associated risk. However, there is some evidence that early stages of diabetic nephrophathy with renal vasodilatation and hyperfiltration could lower circulating ADMA, while in later stages of renal insufficiency, ADMA levels rise [8, 36] . The predictive value of ADMA could therefore be highly dependent on the selection of study subjects. In this context another Page 12 of 31 Diabetes Care possible bias is that we investigated older, obese subjects and results might be different in younger cohorts with lower BMI.
The association between SDMA, rs28305 and CVD in our study adds to increasing evidence that links SDMA with macrovascular disease. In previous studies, SDMA was an independent predictor of mortality or CVD events in patients with prevalent CVD [17] [18] 28] . To date, no data is available on the associations of SDMA or SNPs in AGXT2 and CVD in patients with diabetes. Therefore, it is interesting to note that in our cohort, SDMA was more strongly related to CVD than ADMA in unadjusted analyses. Furthermore, the independent association of AGXT2 rs28305 with intermittent claudication strengthens the hypothesis that SDMA might be both a marker of increased risk, and involved in the mechanisms leading to vascular disease, which are most likely NOS-independent. There is some evidence linking SDMA to an increased release of reactive oxygen species (ROS) as well as proinflammatory cytokines [29] [30] . Because the development of macroangiopathy in type 2 diabetes is associated with chronic sub-clinical inflammation [31] , it would be important to investigate the molecular mechanisms which connect SDMA, inflammation, and macrovascular disease in diabetes patients.
Determinants of dimethylarginines
Consistent with our results, Abhary and coworkers reported that several tag SNPs in the DDAH1 gene were associated with ADMA levels in an elderly cohort of patients with type 2 diabetes [13] . Moreover, they found a significant, but weaker association of one tag SNP in the DDAH2 gene (rs313183) and ADMA levels. We cannot rule out that the lack of association between DDAH2 and dimethylarginine levels in our group results from the selection of the SNPs, which did not include rs31318.
However, subgroup analysis by retinopathy status among the participants of the above-mentioned study revealed that the majority of the SNPs were associated with ADMA levels in patients without documented diabetic retinopathy. Therefore genetic differences or differences in the clinical manifestation of the disease between the cohorts could have contributed to the discrepancies between the observed associations. Nonetheless, despite the hypothesis that DDAH2 might be the enzyme responsible for degrading plasma ADMA owing to its high expression in vascular tissue [32] , the clinical data indicates a greater contribution of DDAH1 in regulating circulating ADMA levels in patients with type 2 diabetes. This observation is in line with our previous genome-wide association study in a population-based cohort, in which DDAH1 emerged as the only gene locus significantly associated with ADMA in multivariate analysis [33] .
Another enzyme capable of degrading dimethylarginines in vivo is alanine-glyoxylate aminotransferase (AGXT2) [19] [20] . In our study, SNPs in the AGXT2 gene were not related to ADMA but only to SDMA plasma concentrations. AGXT2 rs28305 was significantly associated with SDMA plasma concentrations after adjustment for clinical variables including renal function. This is an interesting observation as SDMA is mainly eliminated via renal glomerular excretionand our results suggest that enzymatic degradation by AGXT2 contributes to SDMA clearance. Preliminary data from our group supports this finding as we observed an association of AGXT2 and SDMA in genome-wide association studies [33] .This observation remains consistent with the close relation between SDMA and renal function, as AGXT2 is predominantly expressed in the kidneys [20] .
Page 14 of 31 Diabetes Care
Discrepancies between previous studies regarding ADMA plasma levels in diabetic patients raise questions about determinants of dimethylarginines in diabetes and their associations with glycemic state and diabetes medication. In our cohort, there were nominally significant, but weak positive correlations of ADMA with fasting glucose levels and of SDMA with BMI, but neither of the dimethylarginines were significantly related to HbA1c or diabetes treatment. In line with our results, previous studies found that ADMA was related to markers of renal function and L-arginine plasma concentrations, but not to diabetes duration, glucose concentrations, HbA1c or insulin therapy in patients with type 2 diabetes [9, 26] . In a population-based study, including diabetic and non-diabetic subjects, ADMA levels were associated with age, BMI and smoking status, but these clinical variables only explained approximately 3.5% of interindividual variation in ADMA [7] . In contrast, the multivariable model in our study, including rs7554597 and the precursor molecule L-arginine, was able to explain 21.6% of the variation of ADMA. In another sample of the same population based cohort, SDMA plasma levels were related to age, creatinine, homocysteine, BMI and diastolic blood pressure, very similar to our results [27] . However, while the multivariate model including these parameters was only able to account for 8% of variation in SDMA levels, the multivariate model we used explained 44.5% of the interindividual variation in circulating SDMA. Therefore, it is important to consider the regulatory pathways of dimethylarginines including genetic variation in the metabolizing enzymes when assessing the determinants of ADMA or SDMA in diabetic patients, whereas the contribution of glycemic control or antihyperglycemic agents seems to be only minor. 
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